Atogepant: Mechanism of action, clinical and translational science
Abstract Since the discovery of calcitonin gene‐related peptide (CGRP) in 1982, its integral role in migraine pathophysiology, specifically migraine pain, has been demonstrated through cumulative scientific discoveries that have led to the development and approval of migraine‐specific therapeutics....
Saved in:
Main Authors: | Ramesh Boinpally (Author), Mohamad Shebley (Author), Joel M. Trugman (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ubrogepant: Mechanism of action, clinical and translational science
by: Ramesh Boinpally, et al.
Published: (2024) -
Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies
by: Ramesh Boinpally, et al.
Published: (2023) -
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults
by: K. Chris Min, et al.
Published: (2021) -
Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
by: Cohen F, et al.
Published: (2022) -
Upadacitinib: Mechanism of action, clinical, and translational science
by: Mohamed‐Eslam F. Mohamed, et al.
Published: (2024)